Figure 2.

Lack of synergy between trametinib and cediranib in angiosarcoma cell lines in vitro. HAMON (A), ASM5 (B), and SVR (C) angiosarcoma cells were grown in increasing concentrations of cediranib, either alone or in combination with 10 nM trametinib. With 10 nM trametinib alone, HAMON cells had 37% viability, ASM5 had 63% viability, and SVR had 44% viability in the experiments presented. When normalized for the single agent activity of 10 nM trametinib, there was no synergy between cediranib and trametinib in any of the models. Graphs were made in GraphPad Prism 7 (https://www.graphpad.com/scientific-software/prism/). Unedited/cropped images were formatted in Adobe Photoshop 2020 (https://www.adobe.com/) to create the figure layout.